Trials / Completed
CompletedNCT04304534
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial Infarction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,601 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack (myocardial infarction) that happens when a blood vessel in the heart suddenly becomes blocked. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY2433334 | Tablet, taken orally once a day. |
| OTHER | BAY2433334 matching placebo | Tablet, taken orally once a day. |
Timeline
- Start date
- 2020-06-17
- Primary completion
- 2022-02-21
- Completion
- 2022-02-21
- First posted
- 2020-03-11
- Last updated
- 2023-04-05
- Results posted
- 2023-04-05
Locations
160 sites across 14 countries: United States, Austria, Belgium, Czechia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04304534. Inclusion in this directory is not an endorsement.